ADXS - Advaxis rallies on first milestone payment under ADXS31-164 licensing agreement

Advaxis ([[ADXS]] +15.2%) received the first milestone payment related to its licensing agreement for ADXS31-164, now known as OST-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans.Under the agreement, Advaxis will receive additional clinical, regulatory, and sales-based milestone payments as well as royalties on future product sales.OS Therapies, in collaboration with the Children's Oncology Group, is responsible for the conduct and funding of a clinical study evaluating OST-HER2 in recurrent, completely resected osteosarcoma; it secured funding to support this research, triggering the first milestone payment.Financial terms details have not been disclosed.

For further details see:

Advaxis rallies on first milestone payment under ADXS31-164 licensing agreement